Amalfi Bio is a clinical-stage pharmaceutical company developing a first-in-class, injectable for targeted fat reduction. With a dual focus on precision aesthetic body contouring and a novel treatment for systemic diseases.
About
Our Vision
To revolutionize the medical industry through targeted fat reduction, delivering minimally invasive body contouring, while also addressing fat-driven diseases via precision peri-organ fat reduction—leveraging a single drug platform for both aesthetic and therapeutic applications.
Aesthetic
What Botox Did for Wrinkles, We’re Doing for Fat
Therapeutic
Fat Isn’t Just Unhealthy, It Causes Systemic Disease.
Aesthetic
Until Now, There Has Been No Effective Solution
The promise of spot fat reduction has remained largely unmet. Traditional methods like liposuction are highly invasive, and associated with bruising, swelling, and downtime. The procedure often requires anesthesia and can result in significant complications. Non-invasive energy-based and injectable treatments have struggled to deliver consistent and satisfactory results, leading to underwhelming consumer adoption and limited market growth.
How Is Amalfi Different?
We offer a minimally invasive alternative to surgery that addresses the unmet need for the elimination of areas of stubborn fat deposits. By harnessing a targeted therapy with a natural, biomimetic formulation; our innovation is poised to become the go-to treatment for patients seeking refined, natural-looking body contour. The future of finesse fat reduction is here, and Amalfi Bio will lead the way.
Therapeutic
Our Approach
We developed breakthrough injectable therapies that precisely target peri-organ fat, reducing pathological signaling and slow systemic disease progression at the source. At the same time, our treatments are designed to be minimally invasive, delivering solutions that enhance both health outcomes and quality of life.
Localized Peri-organ Fat Acts as an Endocrine Gland*
It releases growth factors and cytokines (adipokines) stimulating cancer growth, contributing to systemic hypertension, BPH, PCOS, and congestive heart failure, to name a few. The larger the fat pad, the more adipokines released.
Amalfi Bio is the First Targeted Treatment for Peri-Organ Fat
Amalfi’s injectable lipolysis drug is delivered directly into peri-organ fat reducing volume and pathological signaling capability to organs – prostate, kidney, ovaries, heart, pancreas, intestine and liver.
One Product and MOA Treats Systemic Diseases at their Origin
Most therapies target one cytokine or growth factor; Amalfi’s approach targets all adipokines secreted by the fat, without the side effects of systemic medications.
*Drewa et al. Cancers 2025, 17, 372, Grigoras et al. J. Clin. Med. 2021, 10, 1291, Cao et al. Journal of Cancer 2024, 15, 204Pipeline
Meet the Team
J Christopher Marmo, Ph.D.
CEO
Former Founder and CEO of Evolus (EOLS)
Senior Vice President at Allergen
John Joseph, M.D.
CMO
Facial Plastic Surgeon and KOL
Clinical Investigator in 100 Aesthetic Trials
Alec Marmo, Ph.D.
VP R&D
Expertise in Surfactants and Nanoparticles
Formerly with J&J Vision